Pipeline
Advancing Novel Orally Delivered Enzyme Therapies
Anagram Therapeutics' ANG003: A Novel Class of Enzyme Replacement
Anagram’s patient-focused drug development model allows us to build a pipeline focused on innovative treatments to help people living with rare diseases. The company’s pipeline features development programs in rare diseases associated with gastrointestinal, pancreatic and metabolic diseases.
ANG003 is Anagram’s lead product for the treatment of exocrine pancreatic insufficiency (EPI). ANG003 is a new class of broad-spectrum recombinant digestive enzyme replacement therapy, targeting some of the most challenging diseases in infants, children, and adults. People with EPI do not produce enough pancreatic (digestive) enzymes to break down foods and absorb nutrients, which can lead to malnutrition, fatty acid abnormalities, profound gastrointestinal symptoms, a significant decrease in quality of life and reduced life expectancy. ANG003 was engineered to be stable and immediately active in the gastrointestinal tract to maximize digestion and absorption. ANG003 contains lipase for fat malabsorption, protease for protein malabsorption, and amylase for carbohydrate malabsorption. People with EPI are currently treated with pancreatic enzyme replacement therapies (PERT) from pig pancreas glands that have a high treatment burden for patients, requiring 15-40 capsules per day. Pig-derived PERT require a significant amount of plastic coating to prevent it from being degraded in the stomach. PERT derived from pig pancreas glands continue to experience global product shortages.
On this journey, we know the need for better treatment options is urgent – that is why our team works with the rare disease patient community, including the Cystic Fibrosis Foundation, to identify, develop, and deliver potentially life-changing therapies. In pursuit of this mission, we continuously seek to understand the perspectives of people living with rare diseases and to forge new paths to make a difference in their lives and provide hope – today and tomorrow.
At Anagram, we are developing a deep pipeline of products that use the power of orally delivered enzymes as therapeutics to solve complex problems.
Click the + to get details on each candidate.
New class of enzyme replacement therapy seeking to provide unparalleled performance with broad-spectrum composition (lipase for fat, protease for protein, amylase for carbohydrate) in order to make a life-changing impact for people who require oral ERT.
Engineered recombinant enzyme seeking to avoid the severe complications associated with congenital enzyme deficiencies.
Engineered to break down specific macronutrient abnormalities due to pancreatic dysfunction.
Engineered recombinant enzyme seeking to avoid buildup in the body of toxic metabolites associated with congenital enzyme deficiencies.